For many treatment methods outlined above, including dietary modifications, NADPH oxidase inhibitors, mitochondrial antioxidants, and xanthine oxidase inhibitors, randomized clinical trials have not been conducted in human cystic kidney disease patients. This evidence concerns the gene FMO5 and cystic kidney disease.